Voltage-gated calcium channel (VGCC) (VGCC)

Voltage-gated calcium channels (VGCCs) are critical transducers of electrical activity into biological signals in pancreatic beta cells (endocrine-abstracts.org, nih.gov). Upon glucose-induced closure of ATP-sensitive potassium (KATP) channels, the resulting membrane depolarization triggers the opening of VGCCs, primarily the L-type (Cav1.2 and Cav1.3) and P/Q-type (Cav2.1) isoforms (nih.gov, rupress.org). This allows a rapid influx of calcium ions into the cytosol, which directly initiates the exocytosis of insulin-containing secretory granules (nih.gov, researchgate.net). Beyond their role in acute insulin release, VGCCs are involved in beta-cell proliferation, survival, and gene expression through excitation-transcription coupling (rupress.org, frontiersin.org). Dysregulation of these channels, such as gain-of-function mutations or chronic overstimulation, is linked to hyperinsulinism and the eventual failure of beta cells in type 2 diabetes (nih.gov, frontiersin.org). Pharmacological modulation of VGCCs, particularly with calcium channel blockers like verapamil, is being explored not only for managing secretion but also for potential beta-cell protective effects in both type 1 and type 2 diabetes (nih.gov, frontiersin.org).

Other names

Voltage-dependent calcium channelVDCCL-type calcium channelHigh voltage-gated calcium channel (HVCC)Cav1.2Cav1.3Cav2.1Cav2.3Cav3.1Voltage-gated calcium channels in pancreatic β cells

Voltage-gated calcium channels (VGCCs) in pancreatic beta cells act as the primary gateway for calcium entry following membrane depolarization (nih.gov). This depolarization is typically initiated by the closure of ATP-sensitive potassium (KATP) channels in response to glucose metabolism (researchgate.net). The resulting rise in intracellular calcium concentration ([Ca2+]i) triggers the fusion of insulin-containing vesicles with the plasma membrane, leading to insulin secretion (nih.gov). Drugs targeting these channels either block the pore (e.g., calcium channel blockers like verapamil) to reduce calcium influx and insulin release, or activate the channel (e.g., Bay K8644) to enhance secretion (nih.gov, acs.org).